Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trial.

Nature cancer·2026
Same author

Minimal residual disease assessment through ctDNA facilitates tailored immunotherapy in MSI-high, NTRK1-fusion pancreatic adenocarcinoma.

The oncologist·2026
Same author

Stakeholder-Informed Needs Assessment for Open Notes Curriculum in Inpatient Pediatrics.

Academic pediatrics·2026
Same author

TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden-High Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

Blood·2026
Same author

Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing.

Leukemia·2025
Same journal

Future Challenges of Molecular Imaging in Oncology.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Clinical Applications of Theranostics.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Internal Radiation Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

The Role of Molecular Imaging in Ion Beam Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Molecular Imaging in Photon Radiotherapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Advancements in Intraoperative Imaging for Enhanced Surgical Precision.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
See all related articles

Related Experiment Video

Updated: Feb 7, 2026

Analysis of Effect of Compound Salt Stress on Seed Germination and Salt Tolerance Analysis of Pepper Capsicum annuum L.
08:27

Analysis of Effect of Compound Salt Stress on Seed Germination and Salt Tolerance Analysis of Pepper Capsicum annuum L.

Published on: November 30, 2022

5.3K

Larotrectinib (LOXO-101).

Stephanie Berger1, Uwe M Martens2, Sylvia Bochum2

  • 1Cancer Center Heilbronn-Franken, MOLIT Institute, SLK-Kliniken Heilbronn GmbH, Am Gesundbrunnen 20-26, 74078, Heilbronn, Germany. stephanie.berger@slk-kliniken.de.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|August 3, 2018
PubMed
Summary
This summary is machine-generated.

Identifying specific gene fusions in cancer is key for targeted therapy. Larotrectinib, a TRK inhibitor, shows significant clinical benefit for patients with NTRK gene fusions.

Keywords:
LOXO-101LarotrectinibNTRK genesTRK receptor family

More Related Videos

Deep Neural Networks for Image-Based Dietary Assessment
13:19

Deep Neural Networks for Image-Based Dietary Assessment

Published on: March 13, 2021

10.0K
Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay
05:21

Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay

Published on: September 13, 2024

908

Related Experiment Videos

Last Updated: Feb 7, 2026

Analysis of Effect of Compound Salt Stress on Seed Germination and Salt Tolerance Analysis of Pepper Capsicum annuum L.
08:27

Analysis of Effect of Compound Salt Stress on Seed Germination and Salt Tolerance Analysis of Pepper Capsicum annuum L.

Published on: November 30, 2022

5.3K
Deep Neural Networks for Image-Based Dietary Assessment
13:19

Deep Neural Networks for Image-Based Dietary Assessment

Published on: March 13, 2021

10.0K
Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay
05:21

Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay

Published on: September 13, 2024

908

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Identifying oncogenic drivers for targeted therapy is a major challenge in cancer research.
  • Gene fusions, such as BCR-ABL and ALK, are established drivers of carcinogenesis that can be targeted by drugs.
  • NTRK gene fusions are increasingly recognized as significant, targetable aberrations in various cancers.

Purpose of the Study:

  • To highlight the importance of NTRK gene fusions as therapeutic targets in oncology.
  • To discuss the development and efficacy of TRK inhibitors, specifically Larotrectinib.

Main Methods:

  • Review of existing research on gene fusions and targeted therapies.
  • Focus on the mechanism of action of TRK inhibitors.
  • Clinical data analysis of Larotrectinib in patients with NTRK gene fusions.

Main Results:

  • NTRK gene fusions represent a significant targetable genetic aberration across diverse cancer types.
  • Larotrectinib, a selective TRK inhibitor, has demonstrated substantial clinical benefit.
  • Larotrectinib is effective in both pediatric and adult patients with NTRK gene fusions.

Conclusions:

  • Targeting NTRK gene fusions with inhibitors like Larotrectinib offers a promising therapeutic strategy.
  • The success of Larotrectinib underscores the potential of precision medicine in oncology.
  • Further research into TRK inhibitors may lead to improved outcomes for a broader range of cancer patients.